B-intervention	0	11	Amisulpride
O	12	20	prevents
B-condition	21	27	nausea
I-condition	28	31	and
I-condition	32	40	vomiting
O	41	51	associated
O	52	56	with
O	57	63	highly
O	64	74	emetogenic
O	75	87	chemotherapy
O	87	88	:
O	89	90	a
O	91	101	randomised
O	101	102	,
O	103	109	double
O	109	110	-
O	110	115	blind
O	115	116	,
O	117	124	placebo
O	124	125	-
O	125	135	controlled
O	135	136	,
O	137	141	dose
O	141	142	-
O	142	149	ranging
O	150	155	trial
O	155	156	.

O	157	169	Chemotherapy
O	169	170	-
O	170	177	induced
O	178	184	nausea
O	185	188	and
O	189	197	vomiting
O	198	199	(
O	199	203	CINV
O	203	204	)
O	205	211	remain
O	212	223	significant
O	224	232	clinical
O	233	241	problems
O	241	242	,
O	243	253	especially
O	254	256	in
O	257	260	the
O	261	268	delayed
O	269	274	phase
O	275	276	(
O	276	278	24
O	278	279	-
O	279	282	120
O	283	284	h
O	285	290	after
O	291	303	chemotherapy
O	303	304	)
O	304	305	.

O	306	317	Amisulpride
O	318	320	is
O	321	322	a
O	323	331	dopamine
O	332	334	D2
O	334	335	/
O	335	337	D3
O	337	338	-
O	338	346	receptor
O	347	357	antagonist
O	358	368	previously
O	369	374	shown
O	375	377	to
O	378	380	be
O	381	383	an
O	384	393	effective
O	394	405	intravenous
O	406	416	antiemetic
O	416	417	.

O	418	420	We
O	421	430	conducted
O	431	432	a
O	433	443	randomised
O	443	444	,
O	445	451	double
O	451	452	-
O	452	457	blind
O	458	463	study
O	464	466	to
O	467	479	characterise
O	480	483	the
O	484	488	dose
O	489	497	response
O	498	500	of
O	501	505	oral
O	506	517	amisulpride
O	518	520	in
O	521	528	delayed
O	529	534	phase
O	535	539	CINV
O	539	540	.

B-eligibility	541	553	Chemotherapy
I-eligibility	553	554	-
I-eligibility	554	556	na
I-eligibility	556	557	ï
I-eligibility	557	559	ve
I-eligibility	560	568	patients
I-eligibility	569	578	receiving
I-eligibility	579	588	cisplatin
I-eligibility	589	590	≥
I-eligibility	591	593	70
I-eligibility	594	596	mg
I-eligibility	596	597	/
I-eligibility	597	599	m2
I-eligibility	600	602	or
I-eligibility	603	605	an
I-eligibility	606	619	anthracycline
I-eligibility	619	620	-
I-eligibility	620	636	cyclophosphamide
I-eligibility	637	644	regimen
I-eligibility	645	648	for
I-eligibility	649	655	breast
I-eligibility	656	662	cancer
O	663	671	received
O	671	672	,
O	673	675	on
O	676	679	day
O	680	681	1
O	681	682	,
O	683	685	20
O	686	688	mg
O	689	700	amisulpride
O	701	704	and
O	705	706	8
O	706	707	-
O	707	709	16
O	710	712	mg
O	713	724	ondansetron
O	725	738	intravenously
O	739	747	followed
O	747	748	,
O	749	753	once
O	754	759	daily
O	760	762	on
O	763	767	days
O	768	769	2
O	769	770	-
O	770	771	4
O	771	772	,
O	773	775	by
O	776	778	10
O	778	779	,
O	780	782	20
O	783	785	or
O	786	788	40
O	789	791	mg
O	792	796	oral
O	797	808	amisulpride
O	809	811	or
B-control	812	819	placebo
O	819	820	.

O	821	822	A
O	823	830	control
O	831	836	group
O	837	846	receiving
O	847	855	standard
O	856	861	three
O	861	862	-
O	862	866	drug
O	867	878	prophylaxis
O	879	882	was
O	883	891	enrolled
O	892	895	for
O	896	901	assay
O	902	913	sensitivity
O	914	922	purposes
O	922	923	.

O	924	927	The
O	928	935	primary
O	936	944	endpoint
O	945	948	was
B-outcome-Measure	949	957	complete
I-outcome-Measure	958	966	response
I-outcome-Measure	967	968	(
I-outcome-Measure	968	970	CR
I-outcome-Measure	970	971	)
O	971	972	,
O	973	980	defined
O	981	983	as
O	984	986	no
O	987	993	emesis
O	994	996	or
O	997	1003	rescue
O	1004	1014	medication
O	1015	1018	use
O	1018	1019	,
O	1020	1022	in
O	1023	1026	the
O	1027	1034	delayed
O	1035	1040	phase
O	1040	1041	.

B-total-participants	1042	1047	Three
I-total-participants	1048	1055	hundred
I-total-participants	1056	1064	eighteen
O	1065	1073	subjects
O	1074	1078	were
O	1079	1088	evaluable
O	1089	1092	per
O	1093	1101	protocol
O	1101	1102	.

B-outcome	1103	1105	CR
I-outcome	1106	1110	rate
I-outcome	1111	1112	(
I-outcome	1112	1114	24
I-outcome	1114	1115	-
I-outcome	1115	1118	120
I-outcome	1119	1120	h
I-outcome	1120	1121	)
O	1122	1125	was
B-cv-bin-percent	1126	1128	20
I-cv-bin-percent	1128	1129	%
O	1130	1134	with
O	1135	1142	placebo
O	1143	1146	and
B-iv-bin-percent	1147	1149	46
I-iv-bin-percent	1149	1150	%
O	1151	1155	with
O	1156	1158	10
O	1159	1161	mg
O	1162	1173	amisulpride
O	1174	1175	(
O	1175	1176	p
O	1177	1178	=
O	1179	1180	0
O	1180	1181	.
O	1181	1184	006
O	1185	1190	after
O	1191	1203	multiplicity
O	1204	1214	adjustment
O	1214	1215	)
O	1215	1216	;
O	1217	1219	in
O	1220	1223	the
O	1224	1229	three
O	1229	1230	-
O	1230	1234	drug
O	1235	1242	control
O	1243	1248	group
O	1248	1249	,
O	1250	1252	it
O	1253	1256	was
O	1257	1259	59
O	1259	1260	%
O	1260	1261	.

B-outcome	1262	1268	Emesis
I-outcome	1268	1269	,
I-outcome	1270	1276	nausea
I-outcome	1277	1280	and
I-outcome	1281	1282	0
I-outcome	1282	1283	-
I-outcome	1283	1286	120
I-outcome	1286	1287	-
I-outcome	1287	1288	h
I-outcome	1289	1291	CR
I-outcome	1292	1296	rate
O	1297	1301	were
O	1302	1315	significantly
O	1316	1324	improved
O	1325	1329	with
O	1330	1332	10
O	1333	1335	mg
O	1336	1347	amisulpride
O	1348	1356	compared
O	1357	1359	to
O	1360	1367	placebo
O	1367	1368	.

O	1369	1375	Higher
O	1376	1381	doses
O	1382	1384	of
O	1385	1396	amisulpride
O	1397	1401	were
O	1402	1405	not
O	1406	1410	more
O	1411	1420	effective
O	1421	1425	than
O	1426	1428	10
O	1429	1431	mg
O	1431	1432	.

O	1433	1435	In
O	1436	1444	patients
O	1445	1449	with
O	1450	1455	acute
O	1456	1461	phase
O	1462	1464	CR
O	1464	1465	,
B-outcome	1466	1473	delayed
I-outcome	1474	1479	phase
I-outcome	1480	1482	CR
I-outcome	1483	1487	rate
O	1488	1491	was
B-cv-bin-percent	1492	1494	44
I-cv-bin-percent	1494	1495	%
O	1496	1499	for
O	1500	1507	placebo
O	1507	1508	,
B-iv-bin-percent	1509	1511	75
I-iv-bin-percent	1511	1512	%
O	1513	1516	for
O	1517	1519	10
O	1520	1522	mg
O	1523	1534	amisulpride
O	1535	1536	(
O	1536	1537	p
O	1538	1539	=
O	1540	1541	0
O	1541	1542	.
O	1542	1545	022
O	1545	1546	)
O	1547	1550	and
O	1551	1553	70
O	1553	1554	%
O	1555	1558	for
O	1559	1562	the
O	1563	1564	3
O	1564	1565	-
O	1565	1569	drug
O	1570	1577	control
O	1577	1578	.

O	1579	1581	No
O	1582	1593	significant
O	1594	1605	differences
O	1606	1610	were
O	1611	1615	seen
O	1616	1623	between
O	1624	1630	groups
O	1631	1633	in
O	1634	1640	safety
O	1641	1651	parameters
O	1651	1652	.

O	1653	1664	Amisulpride
O	1665	1667	10
O	1668	1670	mg
O	1671	1677	orally
O	1678	1680	is
O	1681	1685	safe
O	1686	1689	and
O	1690	1698	superior
O	1699	1701	to
O	1702	1709	placebo
O	1710	1712	at
O	1713	1723	preventing
O	1724	1731	delayed
O	1732	1736	CINV
O	1737	1743	caused
O	1744	1746	by
O	1747	1753	highly
O	1754	1764	emetogenic
O	1765	1777	chemotherapy
O	1777	1778	.

O	1779	1790	NCT01857232
O	1790	1791	.
